Virtu Financial LLC Purchases New Position in Guardant Health, Inc. (NASDAQ:GH)

Virtu Financial LLC purchased a new stake in Guardant Health, Inc. (NASDAQ:GH) during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 8,620 shares of the company’s stock, valued at approximately $233,000.

A number of other institutional investors and hedge funds have also bought and sold shares of the stock. Teachers Retirement System of The State of Kentucky acquired a new position in Guardant Health in the 4th quarter valued at about $3,868,000. Eventide Asset Management LLC grew its position in shares of Guardant Health by 8.3% during the 4th quarter. Eventide Asset Management LLC now owns 3,888,146 shares of the company’s stock worth $105,174,000 after purchasing an additional 298,616 shares in the last quarter. Cadian Capital Management LP acquired a new position in shares of Guardant Health during the 4th quarter worth approximately $19,206,000. Capital International Investors grew its position in shares of Guardant Health by 36.7% during the 4th quarter. Capital International Investors now owns 4,001,803 shares of the company’s stock worth $108,249,000 after purchasing an additional 1,074,452 shares in the last quarter. Finally, NEOS Investment Management LLC acquired a new position in shares of Guardant Health during the 4th quarter worth approximately $429,000. Institutional investors and hedge funds own 92.60% of the company’s stock.

Guardant Health Stock Performance

Shares of NASDAQ GH opened at $29.56 on Friday. The company has a debt-to-equity ratio of 16.70, a quick ratio of 5.66 and a current ratio of 5.95. Guardant Health, Inc. has a 52-week low of $15.81 and a 52-week high of $41.06. The firm has a 50 day moving average price of $23.71 and a two-hundred day moving average price of $22.88. The stock has a market cap of $3.62 billion, a P/E ratio of -7.54 and a beta of 1.15.

Guardant Health (NASDAQ:GH) last announced its quarterly earnings results on Thursday, May 9th. The company reported ($0.94) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.94). Guardant Health had a negative net margin of 76.34% and a negative return on equity of 246.47%. The firm had revenue of $168.49 million during the quarter, compared to analysts’ expectations of $150.51 million. As a group, equities analysts forecast that Guardant Health, Inc. will post -3.31 EPS for the current year.

Analysts Set New Price Targets

A number of research analysts have issued reports on GH shares. Guggenheim restated a “neutral” rating on shares of Guardant Health in a research report on Friday, April 5th. Canaccord Genuity Group upped their price target on shares of Guardant Health from $30.00 to $38.00 and gave the stock a “buy” rating in a report on Tuesday, June 4th. Stephens reaffirmed an “overweight” rating and set a $44.00 price target on shares of Guardant Health in a report on Friday, May 24th. Jefferies Financial Group started coverage on shares of Guardant Health in a report on Monday, June 3rd. They set a “buy” rating and a $32.00 price target for the company. Finally, Piper Sandler cut their price target on shares of Guardant Health from $40.00 to $30.00 and set an “overweight” rating for the company in a report on Monday, February 26th. Two equities research analysts have rated the stock with a hold rating and twelve have given a buy rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $36.91.

About Guardant Health

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.